Neurocrine Biosciences Inc (NAS:NBIX)
$ 141.65 -0.35 (-0.25%) Market Cap: 14.26 Bil Enterprise Value: 13.60 Bil PE Ratio: 39.02 PB Ratio: 5.97 GF Score: 89/100

Neurocrine Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 04:15PM GMT
Release Date Price: $76.44 (+1.49%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Okay. Let's get started. Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior Biotech analysts here at JPMorgan. I am joined by Priyanka Grover, [Malcom Kuno] and (inaudible) Smith from the team. Our next presenting company is Neurocrine, and presenting on behalf of the company, we have CEO, Kevin Gorman.

I want to remind all the attendees of this session that there is an ask a question feature in the portal and I would be happy to ask a question on your behalf, if you put a question in the portal. And with that, Kevin, take it away.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Thank you very much, Anupam, and thank you also, JPMorgan for the ability to present here today. I was really looking forward to meeting everyone in person, but we're back in this virtual world. I hope to be able through this presentation has been preparing for it to be able to generate and show you the excitement that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot